跳转至内容
Merck
CN
  • Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis.

Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2014-11-27)
Ike C dela Peña, Arum Yoo, Naoki Tajiri, Sandra A Acosta, Xunming Ji, Yuji Kaneko, Cesar V Borlongan
摘要

Treatment with tissue plasminogen activator (tPA) beyond the therapeutic time window (>4.5 hours post stroke) may produce hemorrhagic transformation (HT). Strategies that could extend the narrow time window of tPA will benefit a significant number of stroke patients. Male Sprague-Dawley rats underwent middle cerebral artery occlusion (MCAo) and given vehicle, tPA (10 mg/kg), or tPA and granulocyte colony-stimulating factor (G-CSF, 300 μg/kg), at 6 hours after MCAo. Twenty-four hours post treatment, G-CSF+tPA-treated stroke rats displayed 25% improvement in neurological functions and 38.9% reduction of hemorrhage, with Western blots showing 1.9- and 1.2-fold increments in Ang-2 expression in the ischemic cortex and striatum, respectively, and 3-fold increase in phosphorylated endothelial nitric oxide synthase expression in the ipsilateral cortex relative to tPA-treated rats. Immunohistochemistry also showed 2- and 2.8-fold increase in von-Willebrand expression, 3.2- and 2.2-fold increased CD34+ expression, and 4- and 13-fold upregulation of VEGFR-2 expression in the ischemic cortex and striatum, respectively, in G-CSF+tPA-treated stroke rats relative to tPA-treated subjects. Altogether, these findings indicate that G-CSF attenuated delayed tPA-induced HT likely via the enhancement of angiogenesis and vasculogenesis. The use of G-CSF to protect the vasculature may improve the clinical outcome of tPA even outside the currently indicated therapeutic window for ischemic stroke.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
D -(+)-葡萄糖, ≥99.5% (GC)
Sigma-Aldrich
D -(+)-葡萄糖, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
2,3,5-氯化三苯基四氮唑, ≥98.0% (HPLC)
Sigma-Aldrich
葡萄糖, 97.5-102.0% anhydrous basis, meets EP, BP, JP, USP testing specifications
Sigma-Aldrich
D -(+)-葡萄糖, ≥99.5% (GC), BioXtra
Supelco
葡萄糖, Pharmaceutical Secondary Standard; Certified Reference Material
USP
右旋糖, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D -(+)-葡萄糖, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
Sigma-Aldrich
D -(+)-葡萄糖, ACS reagent
Supelco
D -(+)-葡萄糖, analytical standard
Sigma-Aldrich
D -(+)-葡萄糖, suitable for mouse embryo cell culture, ≥99.5% (GC)
Sigma-Aldrich
D -(+)-葡萄糖, Hybri-Max, powder, BioReagent, suitable for hybridoma
Sigma-Aldrich
D -(+)-葡萄糖, tested according to Ph. Eur.
Sigma-Aldrich
D-葡萄糖-12C6, 16O6, 99.9 atom % 16O, 99.9 atom % 12C
Sigma-Aldrich
D -(+)-葡萄糖, Vetec, reagent grade, ≥99.5% (HPLC)
Sigma-Aldrich
β-D-阿洛糖, rare aldohexose sugar